Study for the Sensitivity of Gilteritinib in Acute Myeloid Leukemia
Not Applicable
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- JPRN-UMIN000039778
- Lead Sponsor
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Subject has difficulty to give written consent. 2. Subject is judged to be inappropriate for this study by the investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation between plasma inhibitory activity (PIA) and best response during the treatment in the patients who are treated with gilteritinib
- Secondary Outcome Measures
Name Time Method 1. Relationship between the efficacy of gilteritinib and gene mutations 2.Correlation between the efficacy of gilteritinib and minimal residual disease 3.Relationship between PIA and gilteritinib blood levels